Quantcast
Home > Quotes > IMMU
IMMU

Immunomedics, Inc. Common Stock (IMMU) Quote & Summary Data

$14.94
*  
0.57
3.97%
Get IMMU Alerts
*Delayed - data as of Aug. 16, 2019  -  Find a broker to begin trading IMMU now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 15.005 / $ 14.25
Share Volume
1,901,765
50 Day Avg. Daily Volume
1,957,427
Previous Close
$ 14.37
52 Week High / Low
$ 26.99 / $ 11.55
Market Cap
2,868,157,804
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
1,901,765
50 Day Avg. Daily Volume:
1,957,427

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.70

Trading Range

The current last sale of $14.94 is 29.35% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 15.005 $ 26.99
 Low: $ 14.25 $ 11.55

ETFs with IMMU as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
1.77% SPDR Series Trust SPDR S&P Biotech ETF (XBI) -7.66 (-8.71%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

On December 14, 2018, the Company's Board of Directors approved a change in the Company's fiscal year end from June 30 to December 31, effective immediately. The reporting period for this Transition Report on Form 10-K is for the six months ended December 31, 2018 (which we sometimes refer to in the Transition Report as the "Transition Period"). In this Transition Report, our fiscal years are identified according to the calendar year in which they historically ended (e.g., the fiscal years ended June 30, 2018 is referred to as "fiscal 2018," June 30, 2017 is referred to as "fiscal 2017" and June 30, 2016 is referred to as "fiscal 2016," as if we had not changed our fiscal year to a calendar year on December 14, 2018. References in this Transition Report to "fiscal 2019" refer to the year ending December 31, 2019. Overview Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer.  ... More ...  



Risk Grade

Where does IMMU fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 14.43
Open Date:
Aug. 16, 2019
Close Price:
$ 14.94
Close Date:
Aug. 16, 2019


Consensus Recommendation

Analyst Info